for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avid Bioservices Inc

CDMO.OQ

Latest Trade

7.70USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.02

 - 

8.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.70
Open
--
Volume
--
3M AVG Volume
8.30
Today's High
--
Today's Low
--
52 Week High
8.36
52 Week Low
3.02
Shares Out (MIL)
56.51
Market Cap (MIL)
425.53
Forward P/E
-50.20
Dividend (Yield %)
--

Latest Developments

More

Avid Bioservices Says Richard Hancock Notified Board He Was Resigning As Interim President & CEO

Avid Bioservices Reports Q4 Loss Per Share $0.11

Avid Bioservices Names Nicholas Green As President And Chief Executive Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Avid Bioservices Inc

Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company is focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biopharmaceutical products derived from mammalian cell culture. The Company provides a range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The Company’s services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.

Industry

Biotechnology & Drugs

Contact Info

2642 Michelle Dr Ste 200

TUSTIN, CA

92780-7019

United States

+1.714.5086100

http://avidbio.com/

Executive Leadership

Joseph Carleone

Non-Executive Chairman of the Board

Nicholas S. Green

President, Chief Executive Officer, Director

Daniel Ryan Hart

Chief Financial Officer

Richard A. Richieri

Chief Operations Officer

Mark R. Ziebell

Vice President, General Counsel, Corporate Secretary

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-0.510

2019

-0.160

2020

-0.270

2021(E)

-0.150
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.13
Price To Book (MRQ)
10.15
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
10.45
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-17.68
Return on Equity (TTM)
-11.25

Latest News

Latest News

BRIEF-Avid Bioservices Reports Q4 Loss Per Share $0.11

* AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR ENDED APRIL 30, 2020 AND RECENT DEVELOPMENTS

BRIEF-Avid Bioservices Names Nicholas Green As President And Chief Executive Officer

* AVID BIOSERVICES NAMES NICHOLAS GREEN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

BRIEF-Avid Bioservices Says PPP Loan Was Paid In Full To Lender On May 12

* AVID BIOSERVICES INC - PPP LOAN WAS PAID IN FULL TO LENDER ON MAY 12, 2020, RESULTING IN TERMINATION OF PROMISSORY NOTE DATED APRIL 17 Source text: (https://bit.ly/2XepD3Z) Further company coverage:

BRIEF-Avid Bioservices, Aragen Bioscience Enter Agreement To Offer Biotechnology And Pharmaceutical Clients Integrated Solution For Cell Line And Process Development Through Commercial Manufacturing

* AVID BIOSERVICES AND ARAGEN BIOSCIENCE ENTER AGREEMENT TO OFFER BIOTECHNOLOGY AND PHARMACEUTICAL CLIENTS INTEGRATED SOLUTION FOR CELL LINE AND PROCESS DEVELOPMENT THROUGH COMMERCIAL MANUFACTURING Source text for Eikon: Further company coverage:

BRIEF-Avid Bioservices On April 21, Received Loan Proceeds Of About $4.4 Million Under Paycheck Protection Program

* AVID BIOSERVICES INC - ON APRIL 21, RECEIVED LOAN PROCEEDS OF ABOUT $4.4 MILLION UNDER PAYCHECK PROTECTION PROGRAM Source text: [https://bit.ly/3cOyjEl] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Avid Bioservices To Appointment Two Senior Directors Of Business Development With Responsibility For North America, Europe And Asia

* AVID BIOSERVICES ANNOUNCES APPOINTMENT OF TWO SENIOR DIRECTORS OF BUSINESS DEVELOPMENT WITH RESPONSIBILITY FOR NORTH AMERICA, EUROPE AND ASIA Source text for Eikon: Further company coverage:

BRIEF-Avid Bioservices Reports Q3 Loss Per Share $0.06

* AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR THIRD QUARTER FISCAL 2020 AND RECENT DEVELOPMENTS

BRIEF-Avid Bioservices Provides Update On Ongoing Expansion Of Process Development Capabilities And Laboratory Infrastructure

* AVID BIOSERVICES PROVIDES UPDATE ON ONGOING EXPANSION OF PROCESS DEVELOPMENT CAPABILITIES AND LABORATORY INFRASTRUCTURE

BRIEF-Avid Bioservices Selected By Acumen Pharmaceuticals To Lead Process Development And Clinical Manufacture Of Novel Alzheimer's Disease Candidate

* AVID BIOSERVICES SELECTED BY ACUMEN PHARMACEUTICALS TO LEAD PROCESS DEVELOPMENT AND CLINICAL MANUFACTURE OF NOVEL ALZHEIMER’S DISEASE CANDIDATE

BRIEF-Avid Bioservices Announces Proposed Offering Of Common Stock

* AVID BIOSERVICES ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Avid Bioservices, Oncologie Enter Into Asset Assignment, Purchase Agreement For Avid's PS-Targeting Program Including Bavituximab

* AVID BIOSERVICES AND ONCOLOGIE ENTER INTO ASSET ASSIGNMENT AND PURCHASE AGREEMENT FOR AVID’S PS-TARGETING PROGRAM INCLUDING BAVITUXIMAB

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up